A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
Completed
- Conditions
- Ocular HypertensionOpen-Angle Glaucoma
- Interventions
- Other: No Intervention
- Registration Number
- NCT02348476
- Lead Sponsor
- Allergan
- Brief Summary
This study is a retrospective chart review to assess the tolerability and efficacy of treatment with Simbrinza™ used for patients with Open-Angle Glaucoma or Ocular Hypertension.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- Participants treated with Simbrinza™ for Intra-Ocular Pressure (IOP) lowering in at least one eye
- Participants who had at least one-follow-up visit with tolerablity and efficacy data after Simbrinza™ treatment initiation.
Exclusion criteria:
- Active ocular disease other than glaucoma or ocular hypertension
- History of any intraocular surgery or glaucoma laser surgery within 3 months.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Simbrinza™ No Intervention Patients treated with Simbrinza™ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study.
- Primary Outcome Measures
Name Time Method The time to first glaucoma therapy escalation occurrence or discontinuation of Simbrinza® 2 Years
- Secondary Outcome Measures
Name Time Method The time to first glaucoma therapy escalation occurrence 2 Years Specific AEs and SAEs occurring with a frequency of ≥5% 2 Years The time(s) to additional glaucoma therapy escalation occurrence(s) 2 Years